healthbook TIMES. Oncology Hematology
THE HEALTHBOOK COMPANY LTD.
About the journal
healthbook TIMES. Oncology Hematology is an open-access journal published by THE HEALTHBOOK COMPANY LTD. in Switzerland, publishing in english. It is listed in DOAJ according to the sources read. Declared review time at DOAJ: 6 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- THE HEALTHBOOK COMPANY LTD.
- ISSN
- 2673-2092 · 2673-2106
- Country
- Switzerland
- Languages
- english
- Access
- Open access
- Articles in DOAJ
- 233
- Declared review time
- 6 weeks
- Declared peer-review model
- peer_review
- Official website
- https://onco-hema.healthbooktimes.org/
Index listings
- DOAJ · 2022-01-18
- Indexing
- DOAJ
- APC
- —
- Declared review time (DOAJ)
- 6 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
233
Most recent article
3 months ago
Average review time (journal-declared via DOAJ)
6weeks
Works in OpenAlex
219
Last recorded publication year
2026
h-index
4
i10-index
0
From OpenAlex open data (CC0).
Editorial & policy8
- Added to DOAJ
- 2022-01-18
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSS
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 0%
- ORCID iDs in current deposits
- 0%
- Peer-review policy
- View policy
Identity & continuity1
- Source type
- journal
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Economic and Financial Impacts of Cancer
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Show all subjects (50)
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Advanced Breast Cancer Therapies
- Multiple and Secondary Primary Cancers
- Advanced Breast Cancer Therapies
- Ovarian cancer diagnosis and treatment
- Prostate Cancer Treatment and Research
- Multiple Myeloma Research and Treatments
- Multiple Myeloma Research and Treatments
- Prostate Cancer Treatment and Research
- Ovarian cancer diagnosis and treatment
- Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Colorectal Cancer Treatments and Studies
- Breast Cancer Treatment Studies
- Cutaneous lymphoproliferative disorders research
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Palliative Care and End-of-Life Issues
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Palliative Care and End-of-Life Issues
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Endometrial and Cervical Cancer Treatments
- Monoclonal and Polyclonal Antibodies Research
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
Keywords (DOAJ)
- oncology
- hematology
- guidelines
- recommendations
- biomarkers
- drug developments
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ